These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
3 files

A Potential Practical Process for Remdesivir

submitted on 01.06.2021, 08:04 and posted on 08.06.2021, 08:20 by Chen Liujuan, Guowei Zhang, Jinguang Liu, Jianye Jiao, Han Lin, Miao Wu, Xin Zhang
A four-step synthesis of Remdesivir (1) is presented. This work focuses on the yield improvement of step 1, flow chemistry development of step 2 and 3, process optimization of step 4. The literatures reported ( and SI part) step 1 was repeated, but failed in the crystallization, eventually step 1 product was obtained by column chromatography with >98% HPLC purity and 40% IY. The flow chemistry development of step 2(IY: 84%) and 3 (IY: 63%) was achieved and the release of toxic HCN was avoided, the process robustness was improved by flow chemistry. Step 4 was simplified to apply primary alcohol 6 directly (without protection) to react with chiral SM 8. Lewis acid catalysts were screened by HTS and MgI2 gave 50% AY. Cheap and commercially available MgCl2 and NaI were used to replace MgI2, finally Remdesivir (1) was obtained in >99% purity with 40.3% IY.


To enable a lower cost process for production of Remdesivir API

Bill & Melinda Gates Foundation

Find out more...


Email Address of Submitting Author


Asymchem Life Science (Tianjin) Co., Ltd.



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest

Version Notes

version 1.0

Usage metrics